Feasibility of tocilizumab in ICU patients with COVID-19.

Issa, Nahéma; Dumery, Margot; Guisset, Olivier; Mourissoux, Gaelle; Bonnet, Fabrice; Camou, Fabrice

Issa, Nahéma; Dumery, Margot; Guisset, Olivier; Mourissoux, Gaelle; Bonnet, Fabrice; Camou, Fabrice.

Afiliação

Issa N; Medical Intensive Care and Infectious Diseases Unit, Saint-Andre Hospital, Bordeaux, France.
Dumery M; Medical Intensive Care and Infectious Diseases Unit, Saint-Andre Hospital, Bordeaux, France.
Guisset O; Medical Intensive Care and Infectious Diseases Unit, Saint-Andre Hospital, Bordeaux, France.
Mourissoux G; Medical Intensive Care and Infectious Diseases Unit, Saint-Andre Hospital, Bordeaux, France.
Bonnet F; Internal medicine and Infectious Diseases Unit, Saint-Andre Hospital, Bordeaux, France.
Camou F; Medical Intensive Care and Infectious Diseases Unit, Saint-Andre Hospital, Bordeaux, France.

J Med Virol ; 93(1): 46-47, 2021 01.

Article em En | MEDLINE | ID: mdl-32484915

Assuntos

Tratamento Farmacológico da COVID-19; SARS-CoV-2; Anticorpos Monoclonais Humanizados; Síndrome da Liberação de Citocina; Estudos de Viabilidade; Humanos; Unidades de Terapia Intensiva; Receptores de Interleucina-6

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Revista: J Med Virol Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google